A New GERD Drug's U.S. Gamble: Inside the Bora-Onconic Partnership

MAPLE GROVE, Minn. – July 23, 2026 – A quiet announcement from a Minnesota suburb signals a potentially significant shift in a market affecting one in five Americans. Bora Pharmaceuticals, a global contract development and manufacturing organization (CDMO), has partnered with Korean biopharmaceutical firm Onconic Therapeutics. The deal, on its face, is simple: Bora’s facility in Maple Grove will manufacture JAQBO, Onconic’s new treatment for gastroesophageal reflux disease (GERD), for its planned U.S. Phase 3 clinical trial.

But beyond the launch announcement lies a story of strategic ambition, market disruption, and the intricate global supply chains that underpin modern medicine. This isn’t just about producing pills; it’s about a successful Korean drug taking its first, crucial steps toward the lucrative but fiercely competitive U.S. healthcare market. It’s a move that highlights the rising prominence of a new class of drugs and the critical role of manufacturing partners in navigating the high-stakes world of pharmaceutical development.

The Race to Redefine GERD Treatment

For decades, the battle against GERD—the chronic, often painful condition caused by stomach acid backing up into the esophagus—has been fought with proton pump inhibitors (PPIs). Drugs like Prilosec and Nexium became household names, generating billions in sales and providing relief to millions. However, the reign of PPIs is not without its challenges. Research indicates that up to 40% of patients experience suboptimal symptom control, and long-term use has been associated with potential side effects, creating a clear opening for innovation.

Enter the potassium-competitive acid blockers, or P-CABs. This newer class of drugs represents a significant evolution in acid suppression. Unlike PPIs, which require acid activation in the stomach and must be taken before meals, P-CABs work faster, last longer, and can be taken at any time. This improved convenience and efficacy profile has made them the focus of intense development worldwide.

The U.S. market, valued at over $4.5 billion and projected to grow, is the ultimate prize. The first P-CAB, Phathom Pharmaceuticals’ Voquezna (vonoprazan), only recently secured FDA approval for various GERD-related conditions, establishing a regulatory pathway and firing the starting gun for competitors. JAQBO now joins the race, aiming to carve out its own space in a field where a new standard of care is just beginning to emerge.

JAQBO's Journey from Seoul to the U.S.

For Onconic Therapeutics, the journey to Maple Grove began with a triumph at home. JAQBO was celebrated in Korea as the nation’s 37th domestically developed new drug upon its approval in April 2024. Its subsequent launch saw strong prescription growth, validating the drug's clinical promise and providing the commercial momentum for a bold global expansion.

Onconic has already inked commercialization partnerships across Asia, Europe, and Latin America. But a U.S. market entry is a different level of challenge and opportunity. The partnership with Bora is the first tangible step in a long and arduous process. Onconic is not just hiring a manufacturer; it is securing a guide for the treacherous terrain of U.S. drug development.

“Based on our prescription growth in Korea and overseas commercialization achievements, we will proceed with U.S. development preparation without delay and strengthen JAQBO’s global competitiveness,” a representative from Onconic Therapeutics stated. This statement underscores a strategy built on confidence and speed, aiming to leverage its Korean success as a springboard to conquer the world’s largest pharmaceutical market.

The Minnesota Connection: A Gateway to the U.S. Market

This is where Bora Pharmaceuticals and its Minnesota facility move from a logistical detail to a strategic linchpin. For an international company like Onconic, a U.S.-based CDMO with a firm grasp of FDA regulations is not a convenience—it’s a necessity. Bora’s role extends far beyond simple manufacturing. The agreement includes quality control, stability testing, and, most critically, the preparation of the Chemistry, Manufacturing, and Controls (CMC) documentation. This extensive data package is a core component of any New Drug Application and is subject to intense FDA scrutiny.

Bobby Sheng, Chairman and CEO of Bora, articulated this value proposition clearly. “For companies preparing for U.S. clinical development and commercialization, the right manufacturing partner can make a meaningful difference in how quickly a program moves forward,” he said. “We are proud to support Onconic as it prepares JAQBO for planned U.S. clinical development, and this collaboration reflects Bora’s commitment to helping innovative companies move with confidence into highly regulated markets.”

Bora's “Dual Engine” model, integrating manufacturing services with commercial expertise, is designed for precisely this scenario. Its Maple Grove facility is more than a factory; it is a gateway, enabling global innovators to de-risk their entry into the U.S. by ensuring their product is manufactured to the exacting standards the FDA demands.

Navigating the Path to Approval and Beyond

The agreement between Onconic and Bora sets the stage for a pivotal Phase 3 clinical trial. This trial will need to prove JAQBO’s safety and efficacy within a U.S. population, likely comparing it against the established PPIs and, implicitly, the newly approved P-CAB standard set by Voquezna. Success in this trial is the prerequisite for FDA approval, but it is far from the final hurdle.

Even with a powerful clinical profile, Onconic will face significant commercial challenges. It must convince insurers to add JAQBO to their formularies, often in the face of cheaper, generic PPIs. It will also need to educate physicians and patients on the specific benefits its drug offers in an increasingly crowded therapeutic landscape. This partnership is a calculated investment, a foundational move in a multi-year, multi-million-dollar campaign to bring a new medical innovation to American patients. It exemplifies a broader trend where agile biotechs with novel assets team up with global manufacturing powerhouses to turn scientific potential into tangible therapeutic impact.